Swainsonine(1)

CHEMISTRY LETTERS, pp. 31-34, 1985.

SYNTHESIS OF TWO STEREOISOMERS OF SWAINSONINE

Nobuyoshi YASUDA, Hideo TSUTSUMI, and Takao TAKAYA* Central Research Laboratories, Fujisawa Pharmaceutical Company, Ltd., 2-1-6, Kashima, Yodogawa-ku, Osaka 532


Two stereoisomers of swainsonine, (1S,2S,8S,8aR)-1,2,8trihydroxyoctahydroindolizine and the corresponding (1S,2R,8S,8aR) derivative, were synthesized from D-glucose via one step cyclization to the 5-oxo-1,2,8-trihydroxyoctahydroindolizine derivative.

In the previous paper, 1) we reported total synthesis of swainsonine(1), (1S,2R,8R,8aR)-1,2,8-trihydroxyoctahydroindolizine, which possesses immunoregulative activity.²⁾ We became much interested in biological activity of stereoisomers of 1 and their syntheses. In this paper, we wish to report synthesis of two stereoisomers of $\underline{1}$, the corresponding (1S,2S,8S,8aR) isomer(2) and (1S,2R,8S,8aR) isomer(3).

Our synthetic strategy is to build up a key intermediate, 5-oxo-1,2,8-trihydroxyoctahydroindolizine derivative(II), by one-step cyclization from an acyclic compound, 5-amino-7-0-mesyloctanate derivative(I), which could be obtained from D-glucose. Our target compounds, $\underline{2}$ and $\underline{3}$, could be afforded from II (Scheme 1).

Treatment of 3-azido-3-deoxy-1,2-0-isopropylidene- α -D-glucofuranose(4)³⁾ with excess mesyl chloride in pyridine gave the corresponding 5,6-di-O-mesyl derivative($\underline{5}$) (mp 104-108 °C; IR (nujol) 2130 cm⁻¹; ¹H-NMR (CDCl₃) δ 1.33 (s, Me), 1.50 (s, Me), 3.07 (s, Ms), 3.17 (s, Ms), and 5.87 (d, J_{1,2}=4 Hz, H-1)) in 78% yield. Deprotection of the isopropylidene group in 5 with trifluoroacetic acid and water (9:1) at room temperature for 5.5 h, followed by treatment of (carboethoxymethylene)triphenylphosphorane in THF under reflux for 2 h, gave ethyl (2E)-5-azido-7,8-di-O-mesyl-2,3,5-trideoxy-D-gluco-2-octenate(6) as syrup (IR (neat) 2250, 1700, and 1660 cm⁻¹; 1 H-NMR (DMSO-d₆) δ 1.33 (t, J=8 Hz, Et), 3.03 (s, Ms), 3.10 (s, Ms), 4.20 (q, J=8 Hz, Et), 6.27 (d, J_{2.3}=16 Hz, H-2), 6.93 (dd, $J_{2,3}$ =16 Hz, $J_{3,4}$ =5 Hz, H-3)) in 71% yield. Hydrogenation of <u>6</u> in methanol in the

presence of 10% palladium on carbon under 3.5 atmospheric pressure of hydrogen at room temperature gave the expected compound, (1S,2R,8S,8aR)-2-0-mesy1-5-oxo-1,2,8-trihydroxyoctahydroindolizine(7) (mp 169-171 °C; IR (nujol) 1610 cm⁻¹; ¹H-NMR (DMSO-d₆) δ 1.60-2.02 (m, H-7) and 3.27 (s, Ms)) in 19% yield, together with 5,8-imino-7-0-mesyl-2,3,5,8-tetradeoxy-D-gluco-octano-1,4-lactone(8) (mp 153 °C (decomp); IR (nujol) 1770, 1210, and 1180 cm⁻¹; ¹H-NMR (DMSO-d₆) δ 3.20 (s, Ms); FD-MS 266 (M⁺+1)) in 30% yield. The lactone 8 gave 7 in 89% yield on heating it in a mixture of DMF and EtOH. (1:4). Trimethylsilylation of 7 with a mixture of hexamethyldisilazane and trimethylchlorosilane, followed by reduction with boran dimethylsulfide complex in THF under reflux, gave (1S,2R,8S,8aR)-



Scheme 1. Our strategy for synthesis of two stereoisomers of swainsonine.


2-O-mesyl-1,2,8-trihydroxyoctahydroindolizine(<u>9</u>) (mp 117-118 °C; $[\alpha]_D^{23}$ -7.95° (c 4.0, MeOH); ¹H-NMR (DMSO-d₆) & 3.13 (s, Ms); FD-MS 251 (M⁺)) in 28% yield. Treatment of <u>9</u> with sodium benzoate in DMF at 120 °C for 2 h afforded (1s,2s,8s, 8aR)-2-O-benzoyl-1,2,8-trihydroxyoctahydroindolizine(<u>10</u>) as syrup ($[\alpha]_D^{28}$ +16.4° (c 2.65, MeOH); IR (neat) 1710, 1600, and 1550 cm⁻¹; ¹H-NMR (DMSO-d₆) & 7.33-7.77 and 7.87-8.17 (each m, 1 X Bz); FD-MS 277 (M⁺)) in 54% yield. Removal of the benzoyl group in <u>10</u> with sodium methoxide in methanol at room temperature gave (1s,2s,8s,8aR)-1,2,8-trihydroxyoctahydroindilizine(<u>2</u>), a stereoisomer of swainsonine, (mp 122 °C(decomp); $[\alpha]_D^{24}$ +5.03° (c 0.71, MeOH); ¹³C-NMR (CD₃OD) & 20.5, 32.0, 54.4, 62.3, 67.5, 68.1, 78.3, and 82.2; FD-MS 173 (M⁺)) in 38% yield.


Next, we considered that the other stereoisomer <u>3</u> could be synthesized from $3-azido-3-deoxy-1,2-0-isopropylidene-6-0-mesyl-<math>\alpha$ -D-glucofuranose(<u>11</u>) according to a similar manner described above.


Regioselective mesylation of 4 gave the our starting material (11) as syrup

32

(IR (neat) 2160 cm⁻¹; ¹H-NMR (CDCl₃) δ 1.33 (s, Me), 1.50 (s, Me), 3.07 (s, Ms), 4.63 (d, J=3 Hz, OH), and 5.87 (d, J_{1,2}=3 Hz, H-1)) in 93% yield. Deprotection of the isopropylidene group in <u>11</u>, followed by Wittig reaction, gave ethyl (2E)-5-azido-8-O-mesyl-2,3,5-trideoxy-D-gluco-2-octenate(<u>12</u>) as syrup (IR (neat) 2120, 1700, and 1655 cm⁻¹; ¹H-NMR (CD₃OD) δ 1.23 (t, J=7 Hz, Et), 4.23 (q, J=7 Hz, Et), 6.20 (dd, J_{2,3}=15 Hz, J_{2,4}=2 Hz, H-2), and 7.07 (dd, J_{2,3}=15 Hz, J_{3,4}=6 Hz, H-3)) in 8% yield.⁴) Hydrogenation of <u>12</u> gave (1S,2R,8S,8aR)-5-oxo-1,2,8-trihydroxyoctahydroindolizine(<u>13</u>) as syrup ([α]_D²⁵+44.0° (c 1.95, MeOH); IR (neat) 1640-1590 cm⁻¹; ¹H-NMR (CD₃OD) δ 1.70-2.20 (m, H-7) and 2.20-3.36 (m, H-3)) in 36% yield.







a) MsCl/Py b) $CF_3CO_2H-H_2O$ (9:1) c) $Ph_3P=CHCO_2Et/THF$ d) H_2-10 % Pd·C/MeOH e) ((CH₃)₃Si)₂NH-(CH₃)₃SiCl f) BH₃·(CH₃)₂S/THF

Scheme 3. Synthetic scheme of (1S,2R,8S,8aR)-1,2,8-trihydroxyoctahydroindolizine(3). Trimethylsilylation of <u>13</u>, followed by reduction and repeated column chromatography (i, silica gel (Wakogel C-200, 1-butanol-ethanol-chloroform-25% aqueous ammonia 4:4:4:1 (v/v)); ii, CM-Sephadex G-25; iii, silica gel (Wakogel C-200, the same eluant system as i)), gave (1S,2R,8S,8aR)-1,2,8-trihydroxyoctahydroindolizine(<u>3</u>) as syrup ($[\alpha]_D^{21}$ -3.43° (c 0.9, MeOH); ¹³C-NMR (CD₃OD) δ 17.9, 24.5, 44.4, 61.5, 64.3, 72.2, 75.2, and 82.1; FD-MS 174 (M⁺+1)) in 8% yield.

Biological activity of both stereoisomers (2 and 3) is now under investigation.

References

- 1) N.Yasuda, H.Tsutsumi, and T.Takaya, Chem. Lett., 1984, 1201.
- 2) M.Hino, Y.Tsurumi, T.Shibata, H.Terano, M.Kohsaka, H.Aoki, and H.Imanaka, Annual Meeting of the Agricultural Chemical Society of Japan, Abstract, No.3V-3, Tokyo, Apr.1-4 (1984); O.Nakayama, T.Kino, T.Goto, K.Nakahara, H.Terano, M.Kohsaka, H.Aoki, and H.Imanaka, <u>ibid</u>., No.3V-4, Tokyo, Apr.1-4 (1984).
- 3) W.M.zu Reckendorf, Chem. Ber., <u>101</u>, 3802 (1968).
- 4) This reaction condition was not optimized. Many by-products were observed on TLC.

(Received September 25, 1984)